Intellectual property and biotechnology: the European debate.
The European patent system allows for the introduction of moral issues into decisions about the granting of patents. This feature has greatly impacted European debates about the patenting of biotechnology. This essay explores the European experience, in both the European Union and the European Patent Organization. It argues that there has been great confusion surrounding these issues primarily because the Europeans have not developed a general theory about when exclusion from patentability is the best social mechanism for dealing with morally offensive technologies.
Brody
Baruch
B
Center for Medical Ethics, Baylor College of Medicine, TX, USA.
D001709:Biotechnology / Q000941:ethics / Q000266:history / Q000331:legislation & jurisprudence; D001943:Breast Neoplasms / Q000208:ethnology / Q000235:genetics / Q000517:prevention & control; D015925:Cryopreservation / Q000941:ethics; D005062:European Union; D005260:Female; D019398:Genes, BRCA1; D024522:Genes, BRCA2; D020022:Genetic Predisposition to Disease; D005820:Genetic Testing / Q000191:economics / Q000941:ethics; D017408:Guidelines as Topic; D049673:History, 20th Century; D006801:Humans; D018973:Intellectual Property; D007585:Jews / Q000235:genetics; D008297:Male; D028681:Moral Obligations; D010330:Patents as Topic / Q000941:ethics / Q000266:history / Q000331:legislation & jurisprudence; D012743:Sex Preselection; D012935:Social Justice; D013094:Spermatozoa